Gilenya vs Kesimpta
Side-by-side cost comparison based on Medicare Part D data
Gilenya
Fingolimod
Manufactured by Novartis
Kesimpta
Ofatumumab
Manufactured by Novartis
Gilenya costs 32% less per claim than Kesimpta ($5,738.00 vs $8,425.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Gilenya | Kesimpta |
|---|---|---|
| Avg Cost Per Claim | $5,738.00 | $8,425.00 |
| Total Medicare Spending | $1.4B | $1.6B |
| Total Beneficiaries | 22,000 | 22,000 |
| Total Claims | 248,000 | 186,000 |
| Annual Cost/Patient | $64,682.00 | $71,227.00 |
| Year-over-Year Change | -14.8% | +68.4% |
| Generic Available | No | Yes |
| Patent Expiration | Sep 22, 2027 | Jan 31, 2023 |
| Manufacturer | Novartis | Novartis |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Fingolimod | Ofatumumab |
Gilenya vs Kesimpta: What the Data Shows
Gilenya (Fingolimod) and Kesimpta (Ofatumumab) are both used to treat multiple sclerosis. Based on Medicare Part D data, Gilenya costs $5,738.00 per claim, which is 32% less than Kesimpta at $8,425.00 per claim.
Medicare spent $1.4B on Gilenya and $1.6B on Kesimpta. In terms of patient reach, Kesimpta serves more beneficiaries (22,000 vs 22,000).
Year-over-year spending changed -14.8% for Gilenya and +68.4% for Kesimpta. Kesimpta saw significant spending growth, suggesting increased utilization or price increases.
Kesimpta has a generic available, while Gilenya remains brand-only until its patent expires Sep 22, 2027.
Frequently Asked Questions
Gilenya is cheaper at $5,738.00 per claim, compared to $8,425.00 for Kesimpta. That makes Gilenya about 32% less expensive per claim based on Medicare Part D data.
Yes, both Gilenya and Kesimpta are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Kesimpta has a generic version (Ofatumumab) available, which is typically much cheaper. Gilenya is currently brand-only, with patent expiring Sep 22, 2027.
Medicare Part D spent $1.4B on Gilenya covering 22,000 beneficiaries, and $1.6B on Kesimpta covering 22,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.